Coating composition
    63.
    发明公开
    Coating composition 失效
    Überzugsmittel。

    公开(公告)号:EP0259172A2

    公开(公告)日:1988-03-09

    申请号:EP87307814.1

    申请日:1987-09-04

    摘要: A coating composition comprises an anhydride polymer (A) containing a least two cyclic carboxylic acid an­hydride functional groups and a polymer (B) containing at least two functional groups reactive with anhydride groups and selected from hydroxyalkylamino, hydroxyalkoxy­alkylamino, hydroxy-substituted acyloxyalkylamino, hydr­oxy-substituted polyacyloxyalkylamino, mercaptoalkylamino and oxazolidino groups. One of the polymers (A) and (B) comprises at least one flexible polymer chain selected from polyether, polyester, silicone, diene polymer, hydro­genated diene polymer, polyurethane, polyisobutylene and polyacrylate chains. The functional groups character­istic of that polymer are each present as a terminal group at the end of a flexible polymer chain.

    摘要翻译: 涂料组合物包含含有至少两个环状羧酸酐官能团的酸酐聚合物(A)和含有至少两个与酸酐基反应的官能团的聚合物(B),选自羟基烷基氨基,羟基烷氧基烷基氨基,羟基取代的酰氧基烷基氨基, 取代的聚酰氧基烷基氨基,巯基烷基氨基和恶唑烷基。 聚合物(A)和(B)中的一种包含至少一种选自聚醚,聚酯,硅酮,二烯聚合物,氢化二烯聚合物,聚氨酯,聚异丁烯和聚丙烯酸酯链的柔性聚合物链。 该聚合物的特征性官能团各自以柔性聚合物链末端作为末端基团存在。

    8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY

    公开(公告)号:EP3315531A4

    公开(公告)日:2018-06-20

    申请号:EP16813656

    申请日:2016-06-08

    摘要: Disclosed are an 8-arm polyethylene glycol (PEG) derivative (formula 1), manufacturing method and modified bio-related substance thereby, wherein a tetravalent group U and four trivalent groups E c form a highly symmetric octavalent central structure CORE 0 together, L c connects the octavalent center to eight PEG arms having polydiversity or monodiversity and having n 1 -n 8 as the degrees of polymerization thereof. The terminal of one PEG chain is connected to at least one functional group F (k ‰¥ 1), and said PEG chain and F can be directly connected (g = 0) or connected with a divalent linking group L 0 connected with a terminal branched group G (g = 1) therebetween. The latter provides more reacting sites to combine more pharmaceutical molecules, thereby increasing the drug loading capacity. The near-center symmetric structure of the derivative allows more precise control over the molecular weight during large-scale production, thereby facilitating acquisition of a product having a narrower molecular weight distribution. A bio-related substance modified thereby has a more uniform and controllable performance.